je.st
news
Tag: phase
Microsoft's .Net Framework security updates further effort to phase out RC4 encryption
2014-05-14 18:43:30| InfoWorld: Top News
Microsoft released optional security updates Tuesday for various versions of the .Net Framework that prevent the RC4 encryption algorithm from being used in TLS (Transport Layer Security) connections.
Tags: net
security
effort
updates
L-Band Fixed Frequency Synthesizer features low phase noise.
2014-05-14 14:30:45| Industrial Newsroom - All News for Today
Operating at 1575.42 MHz with 10 MHz reference, SFS1575D-LF single frequency synthesizer features typical phase noise of -102 dBc/Hz at 10 kHz and offsets. RoHS-compliant product delivers typical output power of 5 dBm with VCO voltage supply of 5 Vdc while drawing 20 mA (typ) and PLL voltage of 3 Vdc while drawing 14 mA (typ). Supplied in 0.6 x 0.6 x 0.13 in. package, synthesizer features typical 2nd harmonic suppression of -18 dBc and spurious suppression of -70 dBc. This story is related to the following:Phase Locked Synthesizers |
Tags: low
features
fixed
phase
Ignyta: RXDX-101 Phase I Data Abstract Chosen for Oral Presentation at ASCO
2014-05-12 10:06:25| Logistics - Topix.net
Presenter: , M.D., Fondazione IRCCS Istituto Nazionale dei Tumori Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics.
Tags: data
abstract
phase
presentation
Gilead Announces Results from Phase 2 Study Showing Reduction in...
2014-05-11 00:54:46| Biotech - Topix.net
Gilead Sciences, Inc. today announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden in patients with paroxysmal atrial fibrillation .
Tags: in
results
showing
study
Xspray Microparticles AB Announces Positive Phase I Data for HyNap Nilotinib
2014-05-09 06:30:00| Appliances - Topix.net
May 8, 2014. XSpray Microparticles AB today announced that its proprietary HyNapa formulation of nilotinib demonstrated significantly improved uptake and reduced food interaction in a Phase I clinical trial compared to previously reported data for the commercial available formulation of nilotinib.
Tags: data
positive
phase
announces
Sites : [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] next »